Stratifying patients into high- and low-expression groups based on NR1D2 mRNA levels revealed that elevated NR1D2 expression was associated with poorer PFS in stage II/III CRC patients (Figures 4A, B). Here, NR1D2 is linked to colorectal carcinoma.